Key Clinical Takeaways in Newly Diagnosed Multiple Myeloma

Dr. Ajai Chari and NP Samantha Shenoy conclude the program by summarizing the key clinical insights surrounding the management of newly diagnosed multiple myeloma (NDMM) and the evolving role of daratumumab-based treatment strategies. The faculty reflect on the importance of achieving deep and durable responses, the growing clinical relevance of minimal residual disease (MRD) assessment, and the value of long-term follow-up data in informing frontline treatment decisions. They discuss how contemporary evidence from studies such as MAIA and CEPHEUS has contributed to current treatment paradigms while emphasizing the need for individualized care based on patient characteristics, treatment goals, and tolerability. Dr. Chari and NP Shenoy reinforce the importance of multidisciplinary collaboration, patient engagement, and ongoing evaluation of emerging evidence to optimize long-term outcomes. The discussion concludes with practical perspectives on integrating clinical trial findings into routine management of patients with NDMM.